Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 2
2007 2
2009 1
2010 2
2011 5
2012 1
2013 1
2014 1
2015 4
2016 2
2017 5
2018 2
2019 1
2021 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
CD160: a unique activating NK cell receptor.
Le Bouteiller P, Tabiasco J, Polgar B, Kozma N, Giustiniani J, Siewiera J, Berrebi A, Aguerre-Girr M, Bensussan A, Jabrane-Ferrat N. Le Bouteiller P, et al. Among authors: giustiniani j. Immunol Lett. 2011 Aug 30;138(2):93-6. doi: 10.1016/j.imlet.2011.02.003. Epub 2011 Feb 13. Immunol Lett. 2011. PMID: 21324341 Review.
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.
Decroos A, Cheminant M, Bruneau J, Carras S, Parinet V, Pelletier L, Lacroix L, Martin N, Giustiniani J, Lhermitte L, Asnafi V, Battistella M, Lemonnier F, De Leval L, Sicard H, Bonnafous C, Gauthier L, Genestier L, Caruso S, Gaulard P, Hermine O, Ortonne N. Decroos A, et al. Among authors: giustiniani j. Haematologica. 2023 Oct 1;108(10):2830-2836. doi: 10.3324/haematol.2022.282220. Haematologica. 2023. PMID: 37165836 Free PMC article. No abstract available.
CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.
Giustiniani J, Dobos G, Moins-Teisserenc H, Eustaquio T, Battistella M, Ortonne N, Ram-Wolff C, Bouaziz JD, Marie-Cardine A, Mourah S, Bagot M, Kupper TS, Clark RA, Bensussan A, de Masson A. Giustiniani J, et al. Blood Adv. 2022 Jun 14;6(11):3507-3512. doi: 10.1182/bloodadvances.2021006512. Blood Adv. 2022. PMID: 35201316 Free PMC article. No abstract available.
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.
Gauci ML, Giustiniani J, Lepelletier C, Garbar C, Thonnart N, Dumaz N, Foussat A, Lebbé C, Bensussan A, Marie-Cardine A. Gauci ML, et al. Among authors: giustiniani j. Cancer Immunol Immunother. 2022 Nov;71(11):2731-2742. doi: 10.1007/s00262-022-03199-0. Epub 2022 Apr 15. Cancer Immunol Immunother. 2022. PMID: 35428910 Free PMC article.
CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases.
Henry A, Boulagnon-Rombi C, Menguy T, Giustiniani J, Garbar C, Mascaux C, Labrousse M, Milas C, Barbe C, Bensussan A, Durlach V, Arndt C. Henry A, et al. Among authors: giustiniani j. Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2679-2686. doi: 10.1167/iovs.18-24021. Invest Ophthalmol Vis Sci. 2018. PMID: 29860454
35 results